A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies

[1]  Yiv.  Nanoscale Small Interfering RNA Delivery Systems For Personalized Cancer Therapy , 2015 .

[2]  Y. Iwakura,et al.  Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. , 2014, The Journal of clinical investigation.

[3]  Hua Lu,et al.  Cationic, helical polypeptide-based gene delivery for IMR-90 fibroblasts and human embryonic stem cells. , 2013, Biomaterials science.

[4]  Qiuhao Qu,et al.  Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation. , 2013, Angewandte Chemie.

[5]  F. Uckun,et al.  Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. , 2013, Blood.

[6]  F. Uckun,et al.  Novel monoclonal antibody-based therapies for leukemia , 2013 .

[7]  Hua Lu,et al.  Reconfiguring the architectures of cationic helical polypeptides to control non-viral gene delivery. , 2013, Biomaterials.

[8]  Qiuhao Qu,et al.  Supramolecular Self-Assembled Nanoparticles Mediate Oral Delivery of Therapeutic TNFa TNFa TNFa siRNA against Systemic Inflammation * * , 2013 .

[9]  F. Uckun,et al.  Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros , 2012, Proceedings of the National Academy of Sciences.

[10]  Hua Lu,et al.  A cell-penetrating helical polymer for siRNA delivery to mammalian cells. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  G. Reaman,et al.  CD22 Exon 12 deletion is a characteristic genetic defect of therapy‐refractory clones in paediatric acute lymphoblastic leukaemia , 2012, British journal of haematology.

[12]  Yao Lin,et al.  Water-Soluble Polypeptides with Elongated, Charged Side Chains Adopt Ultra-Stable Helical Conformations. , 2011, Macromolecules.

[13]  J. Burnett,et al.  Current progress of siRNA/shRNA therapeutics in clinical trials , 2011, Biotechnology journal.

[14]  Yao Lin,et al.  Ionic polypeptides with unusual helical stability. , 2011, Nature communications.

[15]  Shutao Guo,et al.  Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy , 2011 .

[16]  F. Uckun,et al.  CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia , 2010, Proceedings of the National Academy of Sciences.

[17]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[18]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[19]  A. W. Harris,et al.  The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells , 1988, The Journal of experimental medicine.

[20]  C. Song,et al.  Heterogeneity of cultured leukemic lymphoid progenitor cells from B cell precursor acute lymphoblastic leukemia (ALL) patients. , 1987, The Journal of clinical investigation.

[21]  K. Sikora.  Monoclonal antibodies in oncology. , 1982, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.